Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,263,284
  • Shares Outstanding, K 160,561
  • Annual Sales, $ 654,700 K
  • Annual Income, $ -222,690 K
  • 36-Month Beta 2.39
  • Price/Sales 17.53
  • Price/Cash Flow N/A
  • Price/Book 8.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 7
  • High Estimate 0.00
  • Low Estimate -0.40
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +54.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.69 +8.65%
on 02/08/19
78.06 -11.35%
on 02/01/19
-4.41 (-5.99%)
since 01/18/19
3-Month
51.50 +34.37%
on 12/24/18
78.06 -11.35%
on 02/01/19
+13.01 (+23.15%)
since 11/20/18
52-Week
47.75 +44.92%
on 04/25/18
84.37 -17.98%
on 10/03/18
+15.04 (+27.77%)
since 02/20/18

Most Recent Stories

More News
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

MGNX : 22.24 (+0.41%)
LGND : 118.69 (-0.05%)
INCY : 83.36 (-0.86%)
GILD : 66.94 (+0.27%)
SGEN : 69.33 (-1.17%)
REGN : 420.18 (-0.10%)
New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Phillips 66 (NYSE:PSX), Seattle...

PSX : 97.82 (+1.11%)
FRPH : 53.11 (+0.89%)
CJ : 17.66 (+2.79%)
SGEN : 69.33 (-1.17%)
MTBC : 4.61 (-1.28%)
GPRE : 15.42 (+0.52%)
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion

Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

NVO : 49.70 (-1.23%)
MRK : 79.46 (+0.28%)
SGEN : 69.33 (-1.17%)
BMY : 51.12 (-0.47%)
Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS(R) (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing...

TKPYY : 16.5900 (-0.90%)
SGEN : 69.33 (-1.17%)
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.

CELG : 90.44 (-0.28%)
MRK : 79.46 (+0.28%)
SGEN : 69.33 (-1.17%)
IMMU : 14.28 (-0.21%)
Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

SGEN : 69.33 (-1.17%)
Seattle Genetics: 4Q Earnings Snapshot

BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Thursday reported a loss of $119.8 million in its fourth quarter.

SGEN : 69.33 (-1.17%)
Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results

---ADCETRIS Approved by FDA in Combination with Chemotherapy for Frontline CD30-Expressing PTCL-

SGEN : 69.33 (-1.17%)
Biotech Companies Introduce New Treatments as Concern Over Cancer Rises

Cancer is among one of the leading causes of death around the globe; namely, in 2018, there were a total estimated 18.1 million new cases worldwide. The International Agency for Research on Cancer (IARC)...

QBIO : 1.8700 (-2.35%)
CELG : 90.44 (-0.28%)
INCY : 83.36 (-0.86%)
SGEN : 69.33 (-1.17%)
CELGZ : 0.81 (unch)
NKTR : 43.06 (+0.58%)
Seattle Genetics Up 23.1% Since SmarTrend Uptrend Call (SGEN)

SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on January 7th, 2019 at $61.50. In approximately 1 month, Seattle Genetics has returned 23.07% as of today's recent price of $75.68.

SGEN : 69.33 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 72.72
1st Resistance Point 71.44
Last Price 69.33
1st Support Level 69.40
2nd Support Level 68.64

See More

52-Week High 84.37
Fibonacci 61.8% 70.38
Last Price 69.33
Fibonacci 50% 66.06
Fibonacci 38.2% 61.74
52-Week Low 47.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar